
Ionis Pharma (IONS) Stock Forecast & Price Target
Ionis Pharma (IONS) Analyst Ratings
Bulls say
Ionis Pharmaceuticals demonstrates a positive outlook due to its robust pipeline of novel drugs and strong financial performance. The company's higher than anticipated R&D revenue of $141 million, coupled with the successful launch of Wainua generating $42 million in sales and $10 million in royalty revenue, indicates a strong growth trajectory. Additionally, Ionis's favorable payer dynamics, which allow the majority of patients to incur $0 out-of-pocket costs, and the untapped market, with only 20% of patients currently treated, further enhance the company's growth potential in the therapeutic areas it targets.
Bears say
Ionis Pharmaceuticals has faced significant financial challenges, with substantial losses and an anticipated lack of profitability for several years, leading to a negative outlook for the stock. The company's guidance indicates a revenue range for 2025 that falls short of consensus estimates, primarily due to a projected decline in R&D revenue, despite expectations for an increase in commercial revenue. Furthermore, competitive pressures, particularly regarding market share erosion of Spinraza, and uncertain outcomes linked to other product performances, contribute to the risks surrounding the company's financial stability and growth potential.
This aggregate rating is based on analysts' research of Ionis Pharma and is not a guaranteed prediction by Public.com or investment advice.
Ionis Pharma (IONS) Analyst Forecast & Price Prediction
Start investing in Ionis Pharma (IONS)
Order type
Buy in
Order amount
Est. shares
0 shares